Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Average Price Target of $17.75

Key Points

• Analyst sentiment is moderately bullish: Entrada Therapeutics has a consensus “Moderate Buy” rating, with four buys, one hold and one sell. The average 12-month price target is $17.75.
• The stock is trading near its yearly low: Shares opened at $4.37, compared with a 1-year range of $4.11 to $16.45, while remaining below its 50-day and 200-day moving averages.
• Financial results remain weak: Entrada reported a quarterly loss of $1.01 per share versus an expected $0.97 loss and revenue of $0.90 million versus estimates of $2.32 million. Insiders sold roughly $6.7 million of stock over the past three months.

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) have received a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $17.75.

Several analysts have recently weighed in on the company. Wall Street Zen lowered Entrada Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, September 26th. Roth Capital reaffirmed a "buy" rating and set a $11.00 target price on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Finally, Weiss Ratings upgraded shares of Entrada Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 2nd.

Entrada Therapeutics Price Performance

TRDA opened at $4.37 on Friday. The business has a 50 day moving average price of $6.59 and a two-hundred day moving average price of $7.95. The company has a market capitalization of $170.17 million, a price-to-earnings ratio of -1.10 and a beta of -0.24. Entrada Therapeutics has a 1-year low of $4.11 and a 1-year high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Equities analysts expect that Entrada Therapeutics will post -4.03 EPS for the current fiscal year.

Insider Transactions at Entrada Therapeutics

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the firm's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the transaction, the insider owned 3,885,115 shares in the company, valued at approximately $27,700,869.95. This trade represents a 0.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $7.06, for a total transaction of $102,857.14. Following the completion of the transaction, the insider directly owned 4,318,348 shares in the company, valued at $30,487,536.88. This represents a 0.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 946,961 shares of company stock valued at $6,725,291 over the last three months. 9.49% of the stock is owned by corporate insiders.

Institutional Trading of Entrada Therapeutics

Large investors have recently added to or reduced their stakes in the business. State of Wyoming acquired a new position in Entrada Therapeutics in the second quarter worth approximately $37,000. ADAR1 Capital Management LLC bought a new position in shares of Entrada Therapeutics in the second quarter valued at $114,000. Deutsche Bank AG acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at $195,000. Ieq Capital LLC acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at $218,000. Finally, Odyssean LLC acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at $230,000. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc is a biotechnology company focused on developing medicines that address diseases caused by genetic abnormalities. The company's research centers on its proprietary Endosomal Escape Vehicle (EEV) platform, which is designed to transport therapeutic cargo into cells and release it from endosomes, potentially enabling treatment of targets that have been difficult to reach with conventional drug-delivery approaches.

Entrada is developing EEV-based therapeutics using modalities such as oligonucleotides, including compounds intended to modify RNA or influence gene expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.